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Abstract
Background: No selection criteria for helical tomotherapy (HT) based stereotactic ablative radiotherapy (SABR) to treat early
stage non-small cell lung cancer (NSCLC) or solitary lung metastases has been established. In this study, we investigate the
dosimetric selection criteria for HT based SABR delivering 70 Gy in 10 fractions to avoid severe toxicity in the treatment of
centrally located lesions when adequate target dose coverage is desired.
Materials and Methods: 78 HT-SABR plans for solitary lung lesions were created to prescribe 70 Gy in 10 fractions to the
planning target volume (PTV). The PTV was set to have $95% PTV receiving 70 Gy in each case. The cases for which dose
constraints for $1 OAR could not be met without compromising the target dose coverage were compared with cases for
which all target and OAR dose constraints were met.
Results: There were 23 central lesions for which OAR dose constraints could not be met without compromising PTV dose
coverage. Comparing to cases for which optimal HT-based SABR plans were generated, they were associated with larger
tumor size (5.7261.96 cm vs. 3.7461.49 cm, p,0.0001), higher lung dose, increased number of immediately adjacent OARs
( 3.4561.34 vs. 1.6660.81, p,0.0001), and shorter distance to the closest OARs (GTV: 0.2660.22 cm vs. 0.8860.54 cm,
p,0.0001; PTV 0.1960.18 cm vs. 0.4860.36 cm, p=0.0001).
Conclusion: Delivery of 70 Gy in 10 fractions with HT to meet all the given OAR and PTV dose constraints are most likely
when the following parameters are met: lung lesions #3.78 cm (11.98 cc), #2 immediately adjacent OARs which are
$0.45 cm from the gross lesion and $0.21 cm from the PTV.
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Introduction
Helical Tomotherapy (HT) is a technology that delivers fan-
beam intensity-modulated radiotherapy (IMRT) under megavolt-
age computed tomography (MVCT) guidance with continuous
and synchronous gantry rotation and couch movement during
radiation delivery [1]. Image guided IMRT delivered through HT
has been shown to be able to generate highly conformal dose
distribution at various anatomical sites since its clinical adaptation
[2]. When compared with other techniques of radiation delivery,
such as three dimensional conformal radiotherapy (3D-CRT) and
conventional linac based IMRT, it may generate superior normal
tissue sparing and target dose homogeneity as shown in some
studies [3–5]. Therefore, it may provide a dosimetric advantage in
the sparing of critical organs at risk (OARs) in complex cases, such
as the delivery of stereotactic ablative radiotherapy (SABR) in the
treatment of centrally located early stage non-small cell lung
cancer (NSCLC) or solitary lung metastases from other primaries
because of their ability to generate highly conformal dose
avoidance of the OARs. This is of key clinical importance in the
avoidance of severe toxicities associated with SABR (also called
stereotactic body radiation therapy, SBRT), because such toxicities
are mostly associated with central location and close proximity to
critical structures in the thorax [6–10].
We have previously demonstrated the feasibility of HT-based
SABR for the treatment of centrally located lung lesions [11].
However, no guidelines for the selection of optimal candidates for
this procedure was found after a systematic, and extensive search
of the literature on SABR through the PubMed, and Google
scholar search engines. This prompted us to investigate the
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solitary early-stage NSCLC or metastatic lung tumors using the
most common dose fractionation schedule used in our institution,
7G y 610 fractions, which we chose due to the previously reported
excellent local control (.90%) and minimal toxicity associated
with this regimen even for large tumors [12]. A minimal
biologically effective dose of 100 Gy10 or higher is required for
optimal local control [13]. The BED corresponding to this
fractionation schedule is 119 Gy10. This study will provide
preliminary guidelines in the selection of centrally located early
stage NSCLC and solitary lung metastases for designing future
prospective clinical studies on HT-based SABR in the thorax.
Materials and Methods
Patient and tumor characteristics
This study has been approved by the institutional review borad
(IRB) at the University of Arizona. Since no actual human subjects
was involved, no informed consent was needed per IRB. A total of
seventy eight patients who underwent radiation therapy for stage
I-II NSCLC, isolated recurrences from a lung primary, or
metastases to the lung from other primaries in the department
of Radiation Oncology at the University of Arizona from 2005 to
2011 have been included in this study. We retrieved the previous
planning CT’s for each patient to outline the gross tumor. Among
them, 58 centrally located lesions were identified. Central location
is defined as the area within 2 cm of the proximal bronchial tree,
which includes the lower trachea, carina, mainstem bronchi, and
the lobar bronchi. The critical structures are the esophagus, the
heart, the spinal cord, major blood vessels, the distal trachea, and
the proximal bronchial tree in the majority of the cases. Rarely,
the brachial plexus, and the stomach were also in the vicinity of
the gross disease.
Target volume delineation and SBRT treatment planning
All the target delineation was performed in the Pinnacle
treatment planning system (Philips Medical Systems, Bothell, WA).
Afterwards, each patient’s planning CT scan and the contours
were transferred into the Helical Tomotherapy planning system
(Tomotherapy Inc.) for treatment planning. The planning target
volume (PTV) was the clinical target volume (CTV) with a 5 mm
expansion to account for set up errors and residual tumor motion.
The CTV equals to the gross tumor volume (GTV) and its
immediately adjacent areas which are felt to be at high risk for
microscopic disease extension. The lungs, esophagus, spinal cord,
and the heart were contoured for each patient. The major vessels,
major airway and other additional structures were contoured only
when they were adjacent to the GTV.
Treatment plans were generated in the Tomotherapy Hi-Art
planning system using 6 MV photons delivered without a
flattening filter. A binary multi-leaf collimator (MLC) with a leaf
width that projects to a 6.25 mm width at the isocenter which is
85 cm away from the X-ray photon source. In the plans,
longitudinal aperture sizes of 1.05 cm or 2.5 cm, and pitch of
0.3 were used. The nominal dose rate at the isocenter was 870
cGy/min (SAD). A modulation factor of 3 was set at the beginning
of the optimization process. All SBRT plans prescribed 70 Gy
delivered in 10 daily fractions to the PTV with heterogeneity
corrections using the superposition-convolution algorithm.
All plans were optimized to have at least 95% of the PTV
receiving 100% of the prescription dose, which is in accordance
with the American society of therapeutic radiation oncology
(ASTRO)’s white paper [14]. The dose volume constraints used at
our institution are shown in Table 1, which are described in more
detail in our previous publication [11]. These parameters (10
fractions) approximate those used in the RTOG 0236 (3 fractions)
[15] in their biologically equivalent isodose effect, which were
calculated with the linear quadratic formulism using an a/b ratio
of 3. An a/b ratio of 2 and the likelihood for intrafractional patient
motion was also taken into consideration while deriving a
reasonable dose constraint for the spinal cord. Maximum point
dose constraints were used as in line with those used in the RTOG
0236, because the majority of the thoracic OARs other than the
lungs were serial structures, severe damage to even a small point
could be catastrophic as that reported by Onimaru et al [9,16].
Target volume coverage took priority over the dose constraints for
the OARs in each case because of the concern for significant
decrease in tumor control probability (TCP) when there are
significant subvolumes of cold spots [17].
Data analysis
The size and location of the GTV (and PTV); the number of
adjacent critical structures within 2 cm from the edge of the GTV;
and the distances of the GTV and PTV to each of these adjacent
structures, respectively, were recorded for each patient. These
parameters, and the doses to the PTV & the OARs for patients
whose treatment plans met the given dose constraints were
compared to those from patients whose treatment plans did not
met these constraints using the t-test.
Results
The PTV coverage criteria of $95% of the PTV receiving 70
Gy (%PTV70 Gy) was met by all 78 treatment plans. Among them,
dose constraints for the OARs could not be all satisfied in order to
maintain adequate PTV coverage for 23 centrally located lesions
(Centralno). The dose covering 95% of the PTV (D95), %PTV70
Gy, and the maximum dose to the PTV (PTVmax) for this group of
lesions were compared with those for 35 central (Central) and 20
peripheral lesions (Peripheral) for which the HT SABR plans met
all the PTV and OAR dose parameters. The findings are
summarized in Table 2. The PTVmax was significantly higher,
while the D95 and %PTV70 Gy were significantly lower in the
Centralno group.
Table 1. Dose constraints for the prescription dose of 70 Gy
delivered in 10 fractions.
Critical structures Maximum tolerated dose (Gy)
Spinal Cord* 28
Esophagus 44
Major airway 49
Heart 49
Brachial plexus 38.5
Major vessels 49
Stomach 44
Total lung{
V20 20
MLD 9.5
*30 Gy acceptable in selected cases.
{Total lung volume=total volume of both lungs minus that of the GTV.
V20 is the % of the volume receiving 20 Gy. MLD: mean lung dose.
doi:10.1371/journal.pone.0035809.t001
Selection for Tomo SABR
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35809Dose to the lungs
The dose to the lungs is mainly evaluated by the dose to the
total lung (volumeleft lung+volumeright lung2GTV). There was no
statistically significant difference in the volumes of the total lung,
the ipsilateral lung, and the contralateral lung among the three
groups of lesions (p.0.05). The commonly used parameters of the
mean lung dose (MLD), and the volume of the total lung receiving
5 Gy, 10 Gy, and 20 Gy (V5,V 10, and V20) are listed in Table 3.
The V20 was kept to below 20% for all three types of lesions. The
MLD for the total lung appears to be higher in the Centralno
group. However, it was below the MLD constraint for most cases
in this group.
The MLD, V5,V 10, and V20 for the ipsilateral and the
contralateral lungs are also shown in Table 3 to explore the degree
of contralateral lung sparing in HT-based SABR. All three types of
lesions were found to have significantly lower doses to the
contralateral lung comparing to that to the ipsilateral lung
(p,0.0001). Worth mentioning is that the MLD and V20 for the
ipsilateral lung are significantly higher for all the central lesions,
and the contralateral lung’s MLD and V5 are found to be higher in
the Centralno group when compared to the other two groups.
Dose to the other OARs
The maximum dose received by the spinal cord, the esophagus,
the heart, the major airways, and the major vessels is summarized
in Table 4. The Centralno group was found to have significantly
higher doses for all OARs when compared to other two groups of
lung lesions.
Factors influencing the feasibility of HT-based SBRT
A set of tumor factors were investigated to characterize the
lesions in the Centralno group when compared with the other two
groups of lesions. The findings are summarized in Table 5. The
tumor size for the Centralno group was significantly larger. These
central lesions, for which HT-based SABR is not feasible, had
more than 2 critical structures immediately adjacent to the GTV.
In addition, they were significantly closer to the critical structures
with an average OAR to GTV, and PTV distances of 0.26 cm,
Table 2. Dose Coverage of the PTV for the three groups of lung lesions.
Mean (Std. Dev.) p value
Central Centralno Peripheral
Central vs.
Centralno
Central vs.
Peripheral
Centralno vs.
Peripheral
D95 (Gy) 70.60 (0.55) 70.30 (0.50) 70.70 (0.53) 0.0301 0.5587 0.0145
%PTV70 Gy 96.90 (1.19) 95.40 (0.43) 97.90 (0.62) ,0.0001 0.0002 ,0.0001
PTVmax (Gy) 79.10 (4.30) 85.00 (4.01) 75.80 (1.95) ,0.0001 0.0003 ,0.0001
PTV: planning target volume. OARs: Organs at risk. D95: dose covering 95% of the PTV; %PTV70 Gy: percentage of the PTV volume receiving 70 Gy; PTVmax: maximum
dose to the PTV. Std. Dev.: standard deviation; Central: central lesions for which all the dose constraints were met; Centralno: central lesions for which $1 dose
constraints were not met; Peripheral: peripheral lesions.
doi:10.1371/journal.pone.0035809.t002
Table 3. Dose parameters for the normal lung tissue.
Mean (Std. Dev.) P value
Central Centralno Peripheral
Central vs.
Centralno
Central vs.
Peripheral
Centralno vs.
Peripheral
Total lung
V5 20.6 (4.49) 28.8 (13.4) 21.3 (2.67) 0.0085 0.4843 0.0139
V10 14.2 (3.71) 18.5 (10.9) 13.5 (2.94) 0.0775 0.4961 0.0444
V20 9.21 (3.48) 10.6 (6.17) 7.21 (2.91) 0.3342 0.0345 0.0251
MLD (Gy) 5.80 (1.71) 6.96 (3.61) 5.10 (1.19) 0.1607 0.1129 0.0273
Ipsilateral lung
V5 33.3 (10.6) 39.3 (13.7) 32.4 (6.79) 0.0665 0.6975 0.0400
V10 27.1 (8.78) 31.3 (12.7) 24.0 (5.55) 0.1465 0.1164 0.0191
V20 18.1 (7.50) 20.7 (11.8) 12.8 (4.88) 0.3621 0.0062 0.0063
MLD (Gy) 9.64 (3.29) 11.5 (5.74) 7.59 (1.89) 0.1605 0.0049 0.0043
Contralateral lung
V5 8.53 (6.28) 17.5 (14.9) 8.34 (7.57) 0.0105 0.9197 0.0136
V10 1.82 (2.52) 6.09 (10.9) 1.20 (2.18) 0.0847 0.3971 0.0520
V20 0.48 (0.73) 1.33 (2.24) 0.53 (1.03) 0.1487 0.9020 0.5006
MLD (Gy) 1.71 (0.60) 2.69 (1.93) 1.74 (0.37) 0.0261 0.8272 0.0291
Std. Dev.: standard deviation. Central: central lesions for which all the dose constraints were met. Centralno: central lesions for which $1 dose constraints were not met.
Peripheral: peripheral lesions. V5,V 10,a n dV 20: percentage of volume receiving 5, 10, and 20 Gy, respectively. MLD: mean lung dose.
doi:10.1371/journal.pone.0035809.t003
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suggests the most ideal candidates for HT-based SABR should
have GTV#3. 78 cm, or 11.98 cc; PTV#4.90 cm, or 34.43 cc;
#2 separate adjacent structures immediately adjacent to the GTV,
the minimum GTV to OAR distance of $0.45 cm, and the
minimum PTV to OAR distance of $0.21 cm.
The majority of the lesions was in the left or right upper lobes of
the lungs for the centrally located lesions and the peripheral
lesions. They were consisted of 68.42%, 47.82%, and 65% of the
Central, Centralno, and Peripheral groups of lesions (p.0.05).
Discussion
SABR or SBRT has emerged to become a major treatment
approach for early-stage NSCLC or lung metastases with excellent
local control in recent years [18,19]. However, severe toxicities
following SABR have been associated with centrally located
lesions, which are in close proximity to critical organs [7–10]. The
reported fatal complications, mostly grade 5 hemoptysis, are
usually associated with a high dose delivered per fraction. This is
presumably due to excessive radiation dose to the normal
structures (Table 6) [7,8,10,20–23]. Thus, the clinician is faced
with a dilemma in this situation: Lowering radiation dose or
compromising target coverage may be associated with a high risk
of local recurrence and death from tumor progression; or
delivering a high dose of radiation which may lead to potentially
fatal treatment related toxicities. This prompted us to search for an
optimal dose fractionation schedule that may reliably deliver a
high dose to the tumor while respecting the constraints to the
surrounding normal tissues. In a previous study, we demonstrated
that helical tomotherapy, by virtue of its unique radiation delivery
approach, may be the ideal IMRT delivery system when treating
central lesions with SABR because of the sharp dose gradient it
generates, especially for the 7 Gy610 fractions schedule [11].
In the current study, we further characterize the physical and
geometric parameters of solitary lung lesions (central & peripheral)
from patients for whom adequate target and OAR dose
parameters can be satisfied for HT-based SABR. The OAR dose
constraints are in line with those used in the RTOG phase II trial
(0236) on SBRT for peripheral T1-2N0M0 NSCLC in terms of
the isodose effect through the linear quadratic formalism. In
RTOG 0236, only 3.6% grade 4 SBRT related toxicity and no
grade 5 toxicity were reported [15]. The spinal cord dose was kept
lower due to the concern of increased risk for intrafractional
motion when delivering SABR in complicated cases, which often
takes a long time. However, low dose to the spinal cord is easily
achieved in our experience. In challenging cases, we are willing to
accept a maximum spinal cord dose of 30 Gy, which are still
acceptable based on accepted practice of treating metastases
causing spinal cord compression; and QUNTEC recommenda-
tions suggesting that 21 Gy delivered in 3 fractions will translated
to ,1% risk of myelopathy [24]. In addition, SABR/SBRT
treatments delivering a mean linear quadratic 2 Gy equivalent
dose (EQD2) of 36.4 Gy (a/b of 2) as maximum point dose was
Table 4. Maximum dose to the organs at risk (including organs immediately adjacent to the tumor).
Mean (Std. Dev.) P value
Central (Gy) Centralno (Gy) Peripheral (Gy)
Central
vs. Centralno
Central vs.
Peripheral
Centralno vs.
Peripheral
Spinal cord 18.6 (6.75) 23.3 (6.58) 15.8 (4.58) 0.0102 0.1126 0.0001
Esophagus 21.4 (11.0) 37.1 (16.3) 14.5 (5.33) 0.0003 0.0027 ,0.0001
Heart 17.2 (19.8) 31.2 (23.9) 10.5 (13.8) 0.0194 0.1856 0.0011
Major vessels 45.6 (3.98) 68.0 (8.78) - ,0.0001 - -
Major airway 36.9 (13.0) 67.4 (10.6) - ,0.0001 - -
Std. Dev.: standard deviation. Central: central lesions for which all the dose constraints were met. Centralno: central lesions for which $1 dose constraints were not met.
Peripheral: peripheral lesions. Gy: gray.
doi:10.1371/journal.pone.0035809.t004
Table 5. Comparison of the tumor characteristics of the Centralno group of lesions with the Central and Peripheral groups of
lesions.
Central+Peripheral Centralno P value
Mean (Std. dev.) Mean (Std. dev.)
GTV (cm) 3.74 (1.49) 5.72 (1.96) ,.0001
GTV_cc 16.4 (21.5) 51.1 (54.4) 0.0065
PTV (cm) 4.90 (1.48) 6.71 (1.97) ,.0001
PTV_cc 43.2 (38.9) 88.7 (74.7) 0.0100
# of separate group of OARs 1.66 (0.81) 3.45 (1.34) ,.0001
Distance to adjusted structures (GTV cm) 0.88 (0.54) 0.26 (0.22) ,.0001
Distance to adjusted structures (PTV cm) 0.48 (0.36) 0.19 (0.18) 0.0001
Central+Peripheral: central and peripheral lesions for which all the dose constraints were met. Centralno: central lesions for which $1 dose constraints were not met. Std.
dev.: standard deviation. GTV: gross tumor volume. PTC: planning target volume. #: number. cm: centimeter. cc: cubic centimeter. OARs: organs at risk.
doi:10.1371/journal.pone.0035809.t005
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supports our practice of keeping our maximum point dose to
slightly ,30 Gy when it can be easily achieved [25]. In our limited
experience, no toxicity has been encountered in patients who were
treated with the current set of dose constraints used (Table 1).
To our best knowledge, this is the first study to establish a set of
preliminary, yet clinically applicable dosimetric guidelines to aid
the selection of centrally located lesions for HT-based SABR. The
7G y 610 fraction schedule was chosen mainly because concerns of
significant normal tissue toxicity associated with fractionations
schedules of shorter duration when centrally located lesions were
treated [7–10,20–23]. In addition, the treatment time for
delivering a high dose is usually fairly long for helical tomotherapy.
As a result, most institutions usually divide fractional doses $10
Gy into two consecutive treatments of equal dose with pre-
treatment MVCT set up verification before each treatment on a
daily basis. This treatment approach appears to be inconvenient
and time consuming in a busy clinic. On the contrary, the 10
fraction schedule is not only found to be associated with an
excellent toxicity profile with only 1 case of grade 3 pneumonitis
out of 43 patients when fairly large tumors were treated, but also
delivers a fractional dose that can be delivered in 1 treatment with
helical tomotherapy [12]. Thus, this schedule appears to be a very
good choice among many well tested treatment schedules when it
comes to treating central lesions with helical tomotherapy. The
results indicate that large, centrally located lesions that are in close
proximity to multiple OARs are difficult to treat without
overdosing the OARs if optimal target dose coverage is desired.
These lesions tend to be associated with significantly more
heterogeneous dose distribution in the PTV, and more dose
scatter to the contralateral lung (Tables 2 and 3). Larger central
lesions usually are closer to the immediately adjacent critical
thoracic structures than central lesions of a smaller size. Thus,
demanding a sharper dose gradient to be generated between the
PTV’s edge and the immediately adjacent OARs. However, they
are often surrounded by an increased number of OARs, which
greatly limits the entry angle for free entering beams, thus making
adequately covering the PTV without depositing a high dose in the
immediately adjacent structures impossible.
Because of the limitation on intensity modulation imposed by
the increased number of OARs associated with large central
lesions, HT-based SABR may not be the most optimal treatment
technique if optimal target coverage is desired, even if other dose
fractionation schedules are considered. This is evidenced in a study
by Baisden et al using mostly 3 fraction schedules of various doses,
which had to accept less optimal target dose coverage when an
OAR is very close to the tumor [26]. In such situations, a high
dose delivered through a more protracted course while accounting
for tumor shrinkage may be a good alternative to SABR.
However, this will need to be further investigated in the future.
The normal lung dose does not seem to be a decisive factor in
the feasibility of HT-based SABR. V20 is well below 20% for all
cases. V20 below 20% was previously shown to be associated with
only 1 case of maximally grade 3 pneumonitis (2.3%) in a cohort of
patients treated with 7 Gy610 fractions to the GTV [12]. Also, the
MLD for the total lung are well below 14 Gy3 on average in all
cases, which puts them at a low risk for severe radiation
pneumonitis as shown in many studies [19,27]. On the contrary,
the increased number of OARs immediately adjacent to the tumor
target seems to be the key reason for suboptimal critical structure
sparing if adequate PTV dose coverage is to be maintained. As a
result, we propose to use tumor size (both tumor diameter and
volume), the number of separate critical structures immediately
adjacent to the tumor, and the distances of the closest structures to
the GTV and PTV as a starting point in selecting patients for HT-
based SABR.
There are limitations to our study which need to further
investigated. One of them is tumor motion management. HT has
been previously demonstrated to be adequate for treating moving
targets with a hypofractionated course of radiotherapy [28].
Tumor motion can be addressed with four-dimensional (4D) CT
to account for internal tumor motion throughout the entire
respiratory cycle; while set up errors can be further reduced with
HT compatible immobilization devices [29]. 4-D CT has been
adopted in our institution since 2009. However, this is not the
most essential issue in our study, which only needs hypothetical
targets to carry out the investigation. In addition, the prolonged
treatment delivery time of a complex treatment plan associated
with HT may be partially resolved with newer technology, such as
dynamic jaws and dynamic couch which come with the next
generation of HT systems [30]. We recognize that there are other
dose fractionation schedules, which may be used when treating
centrally located lesions. However, as Table 6 illustrates, fatal
complications are more likely to occur with high fractional doses,
which prompted us to take a conservative approach in dose
fractionation selection which is only limited to schedules for which
clinical outcome and toxicity profile were previously reported.
This may help clinicians in designing prospective SABR trials
treating centrally located tumors in the future.
In conclusion, meeting the OAR dose constraints with adequate
PTV target dose coverage criteria is most likely to be accomplished
for lung lesions with the following characteristics: GTV#3.78 cm,
Table 6. Grade 5 toxicity reported in the literature following stereotactic body radiotherapy for centrally located lung cancer.
Study
Dose fractionation schedule linked to fatal
complications Cause of death Incidence of death (%)
Timmerman et al
7
& Fakiris et al
8
20 Gy63F r
{;2 2G y 63 Fr Pneumonia, hemoptysis,
or respiratory failure
4/22 (18.2%)
Song et al
10 12 Gy64 Fr Hemoptysis 1/9 (11.1%)
Oshiro et al
20* 25 Gy61 Fr Hemoptysis 1/21 (4.8%)
Peulen et al
21* 11 Gy63 Fr; 8 Gy65 Fr; 15 Gy63 Fr Hemoptysis 3/11 (27.3%)
Milano et al
22* 4G y 612 Fr; 5 Gy610 Fr Hemoptysis, severe dyspnea, or bronchitis 4/53 (7.5%)
Stauder et al
23 12 Gy64 Fr Bronchial obstruction 1/47 (2.1%)
{Fr: fractions;
*previously irradiated patients.
doi:10.1371/journal.pone.0035809.t006
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structures immediately adjacent to the GTV, and the distances of
GTV and PTV to the OARs of $0.45 cm, and $0.21 cm,
respectively, when the 7 Gy610 fractions schedule is delivered
with HT. As these are only preliminary findings, they will need to
be further validated in a phase I prospective trial evaluating SABR
for early stages NSCLC and/or solitary lung metastases.
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